Introduction 40
Androgens drive male secondary sexual differentiation and maturation. Two main androgens in human, testosterone (T) and dihydrotestosterone (DHT), complex with the same receptor for their action but confer different biological messages. The receptortestosterone complex signals differentiation of Wolffian duct during embryonic life, regulation of secretion of leutinizing hormone by hypothalamic-pituitary axis and 45 spermatognenesis. The receptor-dihydrotestosterone complex promotes development of external genitalia and prostate during embryogenesis and is also responsible for the changes, which occur at puberty in males (Haqq and Donahoe, 1998) .
AR gene mapped to Xq11.2-q12 encodes a protein with 919 amino acids. AR protein has 50 a domain organization consisting of N-terminal domain (NTD), DNA binding domain (DBD) and a C-terminal ligand-binding domain (LBD) . In addition to ligand binding, LBD is also involved in nuclear localization, receptor dimerization and interaction with other proteins (Brinkmann et al, 1989) . Mutations in AR gene are known to cause complete androgen insensitivity syndrome (CAIS) represented by female phenotype, 55 partial androgen insensitivity syndrome (PAIS), with phenotype ranging from predominantly male to female and mild androgen insensitivity syndrome (MAIS) characterized by undermasculinization (Tsukada et al, 1994) or infertility in otherwise normal male individuals (Rajender et al, 2007) .
60
Hundreds of mutations have been reported in AR gene worldwide (Gottlieb et al, 2004;  website: http://www.mcgill.ca/androgendb). Most of these studies are accompanied by 4 functional assays to show the mechanism of the pathogenesis of the mutation. Various mutations in AR gene have resulted either in the loss of androgen binding to the receptor molecule or loss in the transactivation potential of the ligand-AR complex without 65 significant loss in the ligand binding. In our earlier report, we identified a C3693T missense mutation in AR gene in a familial case of CAIS. On the basis of the information from the nature of the mutation and its location in the ligand-binding pocket of the receptor molecule, we proposed that the mutation might have resulted in the loss of the ligand binding (Singh et al, 2006) . We have now conducted in vitro functional assays to 70 prove the mechanism of action of the mutation.
Subjects, Materials and Methods

Subjects and clinical history
The details of the subjects and the clinical record have been provided in our earlier study 75 (Singh et al, 2006) . All the affected individuals in the family matched the clinical features of CAIS. Direct DNA sequencing for the proband and other affected individuals in the family resulted in the identification of L859F mutation. The segregation of the mutation with the disorder in this family indicated this mutation to underlie the disorder. However, the functional significance of this mutation in the pathogenesis of CAIS has now been 80 elucidated by the ligand binding and transactivation assays. This study was approved by institutional ethical committee.
5
Construction of the mutant AR clone
The AR clone (pSVARo) and the reporter clone (pMMTV-Luc) were the kind gifts from Dr. Bruce Gottlieb. We designed the complimentary primers having the mutation in the middle of forward and reverse primers. The two primer sequences were, forward: 5' GACGCTTCTACCAGTTCACCAAGCTCCTG 3'; reverse: 5' 90 CAGGAGCTTGGTGAACTGGTAGAAGCGTC 3'. The whole plasmid molecule bearing the AR clone was amplified using QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), with the primers bearing the desired mutation. The 50 µl PCR reaction consisted of PCR buffer 5.0 µl, each primer 50 pmol, plasmid DNA 50 ng, dNTPs 1.0µl, PfuTurbo DNA polymerase 1.0µl. The reaction was setup under PCR 95 conditions; 95 ºC for 30 seconds followed by 16 cycles of denaturation at 95 ºC for 30 seconds, annealing at 55 ºC for 1 minute and polymerization at 72 ºC for 10 minutes with a final extension at 68 ºC for 10 minutes. The amplicon from the above reaction was digested with Dpn I restriction enzyme to digest the wild type (parental) plasmid molecules. Upon digestion, the amplified product was checked on 1% agarose gel for 100 quantitative and qualitative analyses.
Bacterial transformation and plasmid isolation (miniprep)
The amplified product was used for the transformation in E.coli. 25 ng of the plasmid DNA was transformed into E.coli by heat shock at 42°C for 45 seconds. The Ampicillin 105 resistant colonies were picked up and used for plasmid isolation. The plasmid DNA was isolated with the Mini prep kit (Bangalore Genei, India), following the protocol provided by the manufacturers. The DNA was dissolved in appropriate quantity of TE buffer. After 6 incubating at room temperature for 2 hours, the plasmid DNA was checked on 2% agarose gel for qualitative and quantitative evaluation. 110
Direct DNA sequencing and plasmid isolation (maxiprep)
The plasmid DNA (approximately 400 ng) was directly sequenced to confirm the presence of the mutation in the clone using Big-Dye chain terminator cycle sequencing protocol on 3730 DNA analyzer (Thangaraj et al, 2003) . The plasmid was isolated on a 115 large scale using the maxiprep kit (Qiagen Inc. Valencia, CA, USA) from the mutant colonies following the protocol provided by the manufacturers. The plasmid DNA was evaluated on 2% agarose gel for quantitative and qualitative analyses.
Androgen binding assay 120
About 800 ng of the plasmid was used for transfection of COS1 cells using 4.8 µl lipofectamine (Stratagene, La Jolla, CA, USA). After 72 hours of the transfection, the cells were washed and medium replaced with a medium containing 5% charcoal stripped steroid free serum. After 96 hours, the cells were harvested using 0.01% trypsin-0.02% EDTA in phosphate buffered saline (PBS). The harvested cells were divided into two 125 fractions for Western blotting and ligand binging assays. The cells were counted by using a hemocytometer to adjust the cell density. Equal volumes of cell suspension with same cell density were incubated with 0.5 nmol-2.0 nmol of trimethylenolone (R1881) in the presence and absence of 1000 fold of unlabeled trimethylenolone to determine specific and non-specific ligand binding, respectively. After the incubation, the cells were washed 130 with 2 ml PBS three times to remove any unbound ligand. The cells were lysed with cell 7 lysis solution [50 mM Tris-Cl (pH 8.0), 10 mM EDTA (pH 8.0), 100 mM NaCl, 0.5% (v/v) Triton X-100, 0.01 ml of protease inhibitor mixture (Sigma)/ml]. The whole cell lysate was then mixed with 6 ml of scintillation counting fluid Bio-Safe II (Research Products International Corporation, Illinois, USA) and the disintegrations per second 135 were counted with the liquid scintillation analyzer (1500 TRI-CARB, Packard). The results were expressed as binding sites per 10 5 cells.
Western blotting
The harvested cells were lysed in the Laemmli buffer (50mM Tris with pH 6.8, 2% SDS, 140 10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue) and boiled for 10 minute in a waterbath according to the method of Laemmli (1970) . The cell lysate was centrifuged at 10,000 rpm for 3 minutes and supernatant collected. Protein content of each lysate was estimated in the supernatant by Amido Black method (Kaplan and Pedersen, 1985) . Equal amounts of the protein for different samples were loaded on SDS-145 PAGE (10%) and electrophoresed at 80V in running buffer (25mM Tris, 250mM glycine, 1% SDS with pH 8.3). The resolved proteins were electrophoretically transferred to a nitrocellulose membrane (Hybond C) following the semi-dry method of Towbin (Towbin et al, 1979) . Subsequently the membrane was stained with 0.1% Ponceau S (prepared in 1% acetic acid) to check the efficiency of the transfer. Before hybridization with the 150 antibodies, the membrane was washed with distilled water to remove the Ponceau stain and blocked with 5% (w/v) non-fat milk in TBST (150mM NaCl, 20mM Tris-HCl, 0.1% Tween 20, pH 7.6) for 2 hours at room temperature. Subsequently, the membrane was washed and incubated with 1:10,000 dilution of primary antibody in TBST. After 2-hours 8 of incubation with the primary antibody, the membrane was washed with TBST (3 times, 155 5 minute each) and incubated with 1:1,000 dilution of alkaline phosphatase conjugated secondary antibody in TBST. After 1 hour incubation, the membrane was washed with TBST (3 times, 5 minute each). Upon hybridization, the blot was incubated in alkaline phosphatase buffer (100mM NaCl, 5mM MgCl2, 100mM Tris pH 9.5) to which NitroBlue Tetrazolium Chloride (NBT) (66µl for 10ml of buffer) and 5-Bromo-4-Chloro-3`-160
Indolylphosphate p-Toluidine (BCIP) salt (33µl for 10ml buffer) were added. The blot was incubated in the dark till a distinct band appeared.
Transactivation assays
The cells were plated at a density of 2 x 10 5 in six well plates. Upon 70% confluency 165 stage, the cells were transfected with 300 ng of the mutant or normal AR clones along with 70 ng of B-Gal and 430 ng of MMTV-Luc plasmids using the protocol described above. After 24 hours, the medium was replaced with a medium containing 5% charcoal stripped serum followed by the addition of the ligand (0.5 nmol-2.0 nmol) to the medium.
After 72 hours, the cells were harvested by trypsinization and centrifugation. After 170 washing with PBS, the cells were counted by hemocytometer and adjusted for the uniform cell density. The cells were lysed using cell lysis solution [50 mM Tris-Cl (pH 8.0), 10 mM EDTA (pH 8.0), 100 mM NaCl, 0.5% (v/v) Triton X-100, 0.01 ml of protease inhibitor mixture (Sigma)/ml]. The activity of the co-transfected β-gal assay plasmid was measured using β-gal assay kit (Roche, Palo Alto, CA, USA) to estimate the 175 transfection efficiency. The luciferase activity was measured by luciferase assay system (Promega Corporation, Madison, WI, USA) using TD-20/20 luminometer (Turner 9 Design, Sunnyvale, CA, USA). Transfection efficiency was corrected by the ratio of the luciferase activity to β-gal activity.
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Results
Site directed mutagenesis resulted in the successful incorporation of the mutation C3693T in AR clone. The presence of the mutation in the clone was confirmed by its sequencing in forward and reverse directions. Protein isolation followed by Western blotting and hybridization confirmed the expression of both the wild type and the mutant 185 proteins (Fig 1) . Ligand binding assay showed negligible binding of R1881 to the mutant receptor in comparison to the wild type under all concentrations of the ligand used (Fig   2) . Complementing the results of binding assay, the transactivation assay showed very less activation of the reporter gene in the mutant receptor in comparison to the wild type receptor (Fig 3) . 190
Discussion
Our earlier study on a familial case of CAIS revealed C3693T mutation in exon 7 of AR gene, leading to replacement of leucine with phenylalanine at codon 859 of AR (Singh et al, 2006) . Amino acid residue L859 is a part of ligand binding domain of AR molecule. 195 This residue is highly conserved in diverse species (Singh et al, 2006) . The importance of this amino acid residue in AR function is further strengthened by its critical location in the ligand-binding pocket of the receptor molecule. In the previous study, we hypothesized that the ligand-binding pocket in the mutant receptor is unable to attain proper conformation, resulting in total disruption of ligand binding and hence CAIS. In 200 the present study, we have functionally proved that it is the highly significant loss of ligand binding, which resulted in the disorder in this family.
The in vitro assays revealed that the androgen binding was reduced to negligible levels as a result of the mutation. This could be due to the reason that the mutated amino acid 205 located to LBD. However, the observation of no transactivation in the mutant receptor must be due to the loss of complex formation between androgen and AR protein. The AR protein normally forms complex with the androgen and localizes to the nucleus. But the absence of ligand or failure of ligand binding to the receptor results in the cytoplasmic localization of the receptor with perinuclear distribution, enforcing its faster degradation 210 (Kemppainen et al., 1992) . Therefore, the mutations resulting in complete loss of androgen binding should result in failure of nuclear localization of AR protein, resulting in rapid degradation. Similarly, the complete loss of androgen binding as a result of L859F mutation in the present case would have rendered AR protein non-functional, alongwith its rapid degradation as a result of cytoplasmic localization. 215
Most of the reported mutations associated with androgen insensitivity syndrome localize to LBD and are available at androgen receptor mutation database along with resulting phenotypes (Gottlieb et al, 2004 ) (website: http://www.mcgill.ca/androgendb). The mechanism of pathogenesis of most of these mutations is well supported by the 220 functional assays. The mutations resulting in the replacement of the amino acids by similar other amino acids should result in partial loss of function, while the replacement of an amino acid by a dissimilar amino acid should result in complete loss of function.
However, this did not hold true when we compared the nature of amino acid substitution with the extent of androgen insensitivity for the mutations reported in exon 7 till date 225 (available at AR mutation database). Exon 7 is the second highly mutated region of AR gene after exon 5. More than 37 different types of mutations have been reported in 127 individuals (Gottlieb et al, 2004) . Of these mutations, maximum number (20 mutations) was reported in CAIS cases, followed by PAIS (11 mutations Although, the exact reason behind phenotypic variations is still unknown but few have been explained on the basis of somatic mutations. However, somatic mutations have been able to explain the phenomenon only in few cases of the total more than 25 cases of 245 phenotypic variation reported till date (Gottlieb et al, 2001a; Gottlieb et al, 2001b) . All 12 the patients in the present family exhibited same phenotype, however, the phenotypic variation associated with this mutation cannot be ruled out in further generations if somatic mutations in the androgen responsive tissues result in the back mutation. Certain mutations in AR gene are even known to result in a gradient of the phenotypes in different 250 affected individuals. However, this is the first report of the L859F mutation; therefore phenotypic variations associated with this mutation have to wait for more studies reporting the same mutation.
The patients were given estrogen therapy and operated to construct the female genital 255 organs. We are in communication with the patients to provide genetic counseling for future pregnancies of their normal sibs to abandon the transmission of the mutated Xchromosome to the coming generations. 
